Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)

Dianthus Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• On a quarterly basis, Current Deferred Revenue rose 148.02% year-over-year to $1.2 million in Q4 2025; TTM through Dec 2025 was $1.2 million, a 148.02% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 148.02% from the prior year.
• Current Deferred Revenue climbed to $1.2 million in Q4 2025 per DNTH's latest filing, from $954000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.2 million in Q4 2025 and bottomed at $100000.0 in Q4 2022.
• The 4-year median for Current Deferred Revenue is $289500.0 (2022), against an average of $407900.0.
• Across the five-year window, Current Deferred Revenue changed 0.0% in 2024 and jumped 854.0% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then surged by 379.0% to $479000.0 in 2024, then surged by 148.02% to $1.2 million in 2025.
• Per Business Quant, the three latest DNTH Current Deferred Revenue figures stand at $1.2 million (Q4 2025), $954000.0 (Q3 2025), and $479000.0 (Q2 2025).